Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu
Open Access
- 1 November 1999
- journal article
- research article
- Published by Wiley in Liver Transplantation and Surgery
- Vol. 5 (6), 512-519
- https://doi.org/10.1002/lt.500050601
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxisHepatology, 1997
- Ganciclovir treatment of hepatitis B virus infection in liver transplant recipientsHepatology, 1996
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovirAntiviral Research, 1995
- Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipientsJournal of Hepatology, 1994
- ATTEMPTED RESOLUTION OF ACUTE RECURRENT HEPATITIS B IN A TRANSPLANTED LIVER ALLOGRAFT BY THE ADMINISTRATION OF GANCICLOVIRTransplantation, 1994
- Liver transplantation for hepatitis B virus—associated cirrhosis: A progress reportHepatology, 1994
- Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infectionJournal of Gastroenterology and Hepatology, 1993
- Passive immunoprophylaxis after liver transplantation in HBsAg-positive patientsThe Lancet, 1991
- INHIBITION OF HBV DNA REPLICATION BY GANCICLOVIR IN PATIENTS WITH AIDSThe Lancet, 1989